Gattaz W F, Nevalainen T J, Kinnunen P K
Zentralinstitut für Seelische Gesundheit Mannheim, Finland.
Fortschr Neurol Psychiatr. 1990 Apr;58(4):148-53. doi: 10.1055/s-2007-1001178.
Phospholipase A2 (PLA2) is a key enzyme in the metabolism of phospholipids. PLA2 is enriched in neuronal membranes and plays an essential role in the functioning of membrane structures in the brain. Because a disordered phospholipid metabolism has been postulated in schizophrenia we started in 1985 a series of exploratory studies in an attempt to clarify the role of PLA2 in schizophrenic disorders. Our results can presently be summed up as follows: 1. Drug-free schizophrenics showed significantly higher PLA2 activity in serum and in plasma as compared with healthy controls as well as with nonschizophrenic psychiatric patients; the latter did not differ from the control group with regard to PLA2 activity. These findings suggest that increased PLA2 activity might be specific for schizophrenia. 2. The possibility that increased PLA2 activity is an artifact due to prior neuroleptic treatment could be ruled out as improbable by the findings that a) neuroleptic treatment significantly reduced PLA2 activity, and b) increased PLA2 activity was also found in first-onset, never-treated schizophrenic patients. 3. Increased PLA2 activity in schizophrenic patients was not caused by the entry of pancreatic enzyme into circulation. Our findings in serum rather suggest that the increment reflects increased intracellular enzyme activity. We speculate that our results might reflect an increment of the intraneuronal PLA2 activity in the brain. The activation of PLA2 in the brain was found to result in changes in neuronal function due to alterations in receptor sensitivity as well as in neurotransmitter metabolism. The possibility that such PLA2-induced mechanisms are involved in the pathology of schizophrenia should be investigated in further experiments.
磷脂酶A2(PLA2)是磷脂代谢中的关键酶。PLA2在神经元膜中含量丰富,在大脑膜结构的功能中起重要作用。由于推测精神分裂症存在磷脂代谢紊乱,我们于1985年开始了一系列探索性研究,试图阐明PLA2在精神分裂症中的作用。我们目前的结果可总结如下:1. 与健康对照组以及非精神分裂症精神病患者相比,未服药的精神分裂症患者血清和血浆中的PLA2活性显著更高;后者在PLA2活性方面与对照组无差异。这些发现表明PLA2活性增加可能是精神分裂症所特有的。2. 增加的PLA2活性是先前使用抗精神病药物治疗导致的假象这一可能性可以被排除,因为以下发现:a)抗精神病药物治疗显著降低了PLA2活性,b)在首次发病、从未接受治疗的精神分裂症患者中也发现了PLA2活性增加。3. 精神分裂症患者PLA2活性增加并非由胰腺酶进入循环所致。我们在血清中的发现反而表明这种增加反映了细胞内酶活性的增加。我们推测我们的结果可能反映了大脑中神经元内PLA2活性的增加。已发现大脑中PLA2的激活会由于受体敏感性以及神经递质代谢的改变而导致神经元功能的变化。这种由PLA2诱导的机制是否参与精神分裂症的病理过程应在进一步的实验中进行研究。